
    
      The Phase 1b/2a assessments of the dose-related safety, PK, and initial antiviral efficacy of
      ABI-H0731 in hepatitis B patients will be conducted at approximately 17 different sites to
      meet enrollment goals of 108 chronic hepatitis B patients.
    
  